
By: Lynn Woods A large stage three trial of an experimental rheumatoid arthritis medication, tasocitinib, has met two important goals – the drug provided an improvement in signs and symptoms of the disease in study participants, and it improved their ability to function physically. The study also made some progress towards a third goal – [...]











